Author | Maurie Markman, MD


Maurie Markman on the Groundbreaking TAPUR Trial

March 15, 2017

In this interview we discuss ASCO's first trial, TAPUR (Targeted Agent and Profiling Utilization Registry), which is examining 17 different commercially available drugs in settings outside of their indication.

Uterine Corpus Tumors

November 01, 2015

Carcinoma of the epithelial lining (endometrium) of the uterine corpus is the most common female pelvic malignancy. Factors influencing its prominence are the declining incidence of cervical cancer, longer life expectancy, and earlier diagnosis.

Neoadjuvant Chemotherapy for Ovarian Cancer: The Debate Reconsidered

September 02, 2008

The question of a well-defined role for the use of neoadjuvant chemotherapy in the treatment of ovarian cancer is recognized to be one of the most hotly debated issues in the management of female pelvic malignancies.[1-3] One group of oncologists would argue that it should be the rare patient (eg, with severe comorbidity) who is not a candidate for an initial attempt at maximal cytoreduction.[1]

Management of Ovarian Cancer

April 01, 2006

Over the past 2 decades, we have seen major progress in the management of women with ovarian cancer, with improvements in both overall survival and quality of life. To truly appreciate this progress, it is important to understand the state of affairs regarding the treatment of ovarian cancer in the early 1980s. This paper will discuss that historical background, describe the increasingly favorable impact of evolving treatment paradigms in ovarian cancer, and note future directions for clinical research in this complex disease process.